Loading...
Market
What will be Suven Pharma's revenue growth percentage for FY 2024-2025?
3
Resolution / Starting Odds
Below 5% • 25%
5% - 10% • 25%
10% - 15% • 25%
Above 15% • 25%
Suven Pharma's official earnings report
Story
Suven Pharma Hits All-Time High of Rs 1,245 After US FDA Closes Inspection
Sep 9, 2024, 04:45 AM
Suven Pharma's Hyderabad-based manufacturing facility, operated by its subsidiary Casper Pharma, received an Establishment Inspection Report (EIR) from the US FDA. The inspection, conducted between July 8-12, 2024, was categorized as Voluntary Action Indicated (VAI) and has been deemed closed. Following this disclosure, Suven Pharma's share price surged by up to 3.67%, reaching an all-time high of Rs 1,245 per share on the BSE.
View original story
Similar markets
Less than 5% growth • 25%
5% to 10% growth • 25%
10% to 20% growth • 25%
More than 20% growth • 25%
Negative growth • 25%
0-5% growth • 25%
5-10% growth • 25%
Over 10% growth • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Increase by more than 20% • 25%
Increase by 10-20% • 25%
Increase by less than 10% • 25%
No increase or decrease • 25%
Decrease • 25%
0-5% increase • 25%
5-10% increase • 25%
More than 10% increase • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
0-10% • 25%
10-20% • 25%
20-30% • 25%
More than 30% • 25%
Less than 5% growth • 25%
5% to 10% growth • 25%
10% to 20% growth • 25%
More than 20% growth • 25%
Less than 50% • 25%
50% to 100% • 25%
100% to 200% • 25%
More than 200% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
10-15% • 25%
0-5% • 25%
5-10% • 25%
15% or more • 25%
More than 20% increase • 25%
10%-20% increase • 25%
0%-10% increase • 25%
Decrease • 25%